Complement C3 is a novel plasma clot component with anti-fibrinolytic properties
Joanna‐Marie Howes(University of Cambridge), Angela M. Carter(University of Alabama at Birmingham Hospital), Richard J. Pease(University of Leeds), Kristina F. Standeven(University of Leeds), Anna C. Shore(Trinity College Dublin), Kerrie A. Smith(University of Leeds), Ramzi Ajjan, Katharina Heß(University of Potsdam), Verena Schroeder(University of Bern), Victoria R. Richardson(University of Leeds), Jeffrey N. Keen(University of Leeds), Riyaz Somani(University of Leicester)
Cited by 80
Related Papers
2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes
|European Heart Journal|2023|1.4k
Responsive gels formed by the spontaneous self-assembly of peptides into polymeric β-sheet tapes
|Nature|1997|856
T-lymphocyte Infiltration in Visceral Adipose Tissue
|Arteriosclerosis Thrombosis and Vascular Biology|2008|679
Combined intracavitary thermotherapy with iron oxide nanoparticles and radiotherapy as local treatment modality in recurrent glioblastoma patients
|Journal of Neuro-Oncology|2018|181
Causal Effect of Plasminogen Activator Inhibitor Type 1 on Coronary Heart Disease
|Journal of the American Heart Association|2017|136